Recent News

• 09.29.2025 - Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
• 09.29.2025 - Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
• 09.28.2025 - Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
• 09.28.2025 - Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
• 08.14.2025 - Larimar Therapeutics Reports Second Quarter 2025 Financial Results
• 08.14.2025 - Larimar Therapeutics Reports Second Quarter 2025 Financial Results
• 07.31.2025 - Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
• 07.31.2025 - Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
• 07.31.2025 - Joon Lee- Truist Securities
• 07.31.2025 - Chris Chen - Robert W. Baird & Co.

Recent Filings

• 08.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.31.2025 - 8-K Current report
• 07.31.2025 - 424B5 Prospectus [Rule 424(b)(5)]